Loading…
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $419M | $103M | $-2M | $70M | -0.2% | 8.7% | -86.8% |
| 2024 | $385M | $72M | $-12M | $59M | -1.1% | 8.7% | -78.2% |
| 2023 | $354M | $24M | $-55M | $67M | -5.3% | 5.6% | -475.8% |
| 2022 | $336M | $89M | $15M | $80M | 1.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 335.64 | 354.34 | 385.15 | 418.84 |
| Operating Revenue | - | 335.64 | 354.34 | 385.15 | 418.84 |
| Cost Of Revenue | - | 132.58 | 141.02 | 154.52 | 161.13 |
| Gross Profit | - | 203.07 | 213.32 | 230.63 | 257.71 |
| Operating Expense | - | 170.55 | 207.10 | 232.36 | 236.70 |
| Research And Development | - | 28.20 | 34.17 | 37.10 | 41.04 |
| Selling General And Administration | - | 99.18 | 127.41 | 141.66 | 139.10 |
| Total Expenses | - | 303.12 | 348.13 | 386.88 | 397.82 |
| Operating Income | - | 32.52 | 6.21 | -1.73 | 21.02 |
| Total Operating Income As Reported | - | 32.52 | -40.77 | -1.73 | 21.02 |
| EBITDA | - | 89 | 23.84 | 72.37 | 102.52 |
| Normalized EBITDA | - | 89 | 70.83 | 72.37 | 102.52 |
| EBIT | - | 36.53 | -32.23 | 4.34 | 27.35 |
| Interest Expense | - | 17.77 | 22.92 | 21.52 | 19.74 |
| Net Interest Income | - | -17.77 | -22.92 | -21.52 | -19.74 |
| Other Non Operating Income Expenses | - | 4.01 | 8.55 | 6.07 | 6.34 |
| Other Income Expense | - | 4.01 | -38.44 | 6.07 | 6.34 |
| Interest Expense Non Operating | - | 17.77 | 22.92 | 21.52 | 19.74 |
| Net Non Operating Interest Income Expense | - | -17.77 | -22.92 | -21.52 | -19.74 |
| Pretax Income | - | 18.76 | -55.14 | -17.18 | 7.62 |
| Tax Provision | - | 4.02 | 0.21 | -5.13 | 9.21 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -9.87 | 0 | 0 |
| Net Income Continuous Operations | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Net Income From Continuing And Discontinued Operation | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Net Income From Continuing Operation Net Minority Interest | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Net Income | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Net Income Common Stockholders | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Net Income Including Noncontrolling Interests | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Normalized Income | - | 14.73 | -18.24 | -12.05 | -1.60 |
| Diluted NI Availto Com Stockholders | - | 14.73 | -55.36 | -12.05 | -1.60 |
| Basic Average Shares | - | 156.88 | 158.94 | 160.39 | 160.39 |
| Diluted Average Shares | - | 159.35 | 158.94 | 160.39 | 160.39 |
| Reconciled Depreciation | - | 52.47 | 56.07 | 68.03 | 75.16 |
| Reconciled Cost Of Revenue | - | 123.27 | 130.48 | 140.08 | 142.52 |
| Total Unusual Items | - | 0 | -46.98 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | -46.98 | 0 | 0 |
| Special Income Charges | - | 0 | -46.98 | 0 | 0 |
| Impairment Of Capital Assets | - | 0 | 46.98 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | - | 43.16 | 45.52 | 53.59 | 56.56 |
| Depreciation And Amortization In Income Statement | - | 43.16 | 45.52 | 53.59 | 56.56 |
| General And Administrative Expense | - | 71.77 | 95.38 | 94.22 | 85.38 |
| Other Gand A | - | 71.77 | 95.38 | 94.22 | 85.38 |
| Selling And Marketing Expense | - | 27.41 | 32.02 | 47.44 | 53.72 |
| Amortization | 38.72 | 41.43 | 43.97 | 51.60 | - |
| Amortization Of Intangibles Income Statement | 38.72 | 41.43 | 43.97 | 51.60 | - |
| Depreciation Income Statement | 2.13 | 1.73 | 1.55 | 1.99 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Certara, Inc.this co. | CERT | $873M | -547.16 | 0.82 | -0.2% | 9.65 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Xencor, Inc. | XNCR | $890M | - | 1.40 | -14.5% | - |
| Cullinan Therapeutics, Inc. | CGEM | $887M | -4.03 | 2.17 |
| - |
| - |
| - |
| - |
| -53.8% |
| -3.32 |
| MeiraGTx Holdings plc | MGTX | $886M | -7.76 | -152.99 | 1971.4% | -10.17 |
| Jade Biosciences, Inc. | JBIO | $876M | - | -18.71 | -38.3% | - |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Peer Median | - | -4.18 | 1.79 | -26.4% | -3.43 | |